Nav: Home

Results from the PLATINUM DIVERSITY study presented at TCT 2016

November 01, 2016

WASHINGTON - November 1, 2016 - A dedicated stent study conducted exclusively in women and minority patients evaluated clinical outcomes within the era of contemporary PCI, comparing these results to a parallel cohort of white male patients. Although there were no significant differences in stent-related outcomes, both groups had higher rates of death and myocardial infarction (MI) in the first year following the procedure.

Findings from the PLATINUM DIVERSITY trial were reported today at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Although people of color are expected to represent more than half (52%) of the U.S. population by 2050, current "all-comers" clinical trial design do not result in a random selection of U.S. patients. As a result, women and minorities have been significantly underrepresented in most cardiology trials.

This multicenter, single-arm, prospective "enriched" cohort study enrolled 1,501 women and minorities at 52 sites in the United States. Patient information was pooled with data from the PROMUS ELEMENT PAS Study (PE Plus PAS, n=2,687) and each group was compared with white men enrolled in the PE Plus PAS (n=1,635).

The combined primary endpoint of death, Ml and target vessel revascularization (TVR) at 12 months was 7.6% for white men compared with 9.6% (P=0.08) for minorities and 8.6% (P=0.33) for women. Data from the individual components of the primary endpoint found that minorities had the highest rate of death and MI whereas white men had the highest rate of TVR:
  • Death was 3.7% in minorities (P=0.03) and 3.4% in women (P=0.04) compared with white men (2.2%).

  • MI was 3.1% (P=0.0002) in minorities and 1.9% in women (P=0.06) compared with white men (1.1%).

  • TVR was 5.4% (P=0.97) in minorities and 4.6% in women (P=0.27) compared with white men (5.5%).

"This study draws important attention to differences in clinical outcomes after stent implantation in women and minorities," said Wayne B. Batchelor, MD, MHS, co-principal investigator from Southern Medical Group in Tallahassee, FL. "The adjusted risk of MI and death/MI was higher in minorities versus white men. In addition, the adjusted risk of death/MI was higher in women than white men with a trend towards higher rates of MI. The similar rates of TVR and stent thrombosis among all three groups suggest that 'stent failure' is unlikely to account for the observed differences in outcome. Further study into the cause of these observed gradients of risk is necessary to gain insight into the potential impact on clinical practice."

"The PLATINUM DIVERSITY trial represents an important example of how we can enrich our understanding of outcomes in the underrepresented population. This is the first trial exclusively enrolling women and minorities undergoing PCI and allows for further evaluation of patients who are usually not represented in clinical studies," said Roxana Mehran, MD, Professor of Medicine, Icahn School of Medicine at Mount Sinai and Co-PI of the PLATINUM DIVERSITY study.

The PLATINUM DIVERSITY trial was funded by Boston Scientific. Dr. Batchelor reported grant/research support from Boston Scientific and consulting fees/honoraria from Abbott, Boston Scientific and Medtronic.

The results of the PLATINUM DIVERSITY Trial will be presented on Tuesday, November 1 at 12:45 PM ET in the Main Arena (Ballroom, Level 3) at the Walter E. Washington Convention Center.
-end-
About CRF and TCT

The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and has educated doctors on the latest treatments for heart disease.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world's premier educational meeting specializing in interventional cardiovascular medicine. Now in its 28th year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

For more information, visit http://www.crf.org and http://www.tctconference.com.

Cardiovascular Research Foundation

Related Myocardial Infarction Articles:

Discovery of cells that heal cardiac damage after infarction
Researchers at Cima and the Clinica Universidad de Navarra (Spain) have led an international study identifying the cardiac cells responsible for repairing the damage to this organ after infarction.
CHOP researchers find MIS-C associated with myocardial injury
Using sensitive parameters to assess cardiac function, researchers at Children's Hospital of Philadelphia (CHOP) have found that cardiac involvement in multisystem inflammatory syndrome in children (MIS-C) differs from Kawasaki disease (KD) and is associated with myocardial injury.
Heart attack modeled with human stem cells
A model of ischemic heart disease was developed using human induced pluripotent stem cells (hiPSC).
The relationship between lifetime drinking and non-fatal acute myocardial infarction
New research from the Prevention Research Center of the Pacific Institute for Research and Evaluation suggests that the impact of alcohol consumption on coronary heart disease may be underestimated.
The relationship between mean platelet volume and in-hospital mortality in geriatric patients with ST segment elevation myocardial infarction who underwent primary percutaneous coronary intervention
In the current issue of Cardiovascular Innovations and Applications volume 4, issue 2, pp.
Epicardial coronary artery abnormalities that do not result in myocardial ischemia
What to Do with Epicardial Coronary Artery Abnormalities That do not Result in Myocardial Ischemia?
Dose-dependent effects of esmolol-epinephrine combination therapy in myocardial ischemia
Animal studies on cardiac arrest found that a combination of epinephrine with esmolol attenuates post-resuscitation myocardial dysfunction.
Renal infarction is associated with acute kidney injury in patients with cardiac amyloidosis
Systemic amyloidosis is a major cause of renal injury, mostly due to direct kidney damage caused by deposits of abnormal protein called amyloid, in the kidney parenchyma.
Anesthetic-induced myocardial conditioning: Molecular fundamentals and scope
The objective of this study was to investigate the role that miRNAs play in the cardioprotective effect of halogenated anesthetics.
A role for circadian enhancers to prevent myocardial injury in the perioperative setting
The current study demonstrates a deleterious effect of midazolam administration prior to myocardial ischemia and reveals reduced circadian protein Period 2 (PER2) levels as the underlying mechanism.
More Myocardial Infarction News and Myocardial Infarction Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.